Therapeutic Solutions International, Inc. (TSOI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 888.06 Thousand USD | -17.59% |
| 2022 | 1.07 Million USD | -1.87% |
| 2021 | 1.09 Million USD | 5.55% |
| 2020 | 1.04 Million USD | 5.99% |
| 2019 | 981.62 Thousand USD | 94.66% |
| 2018 | 504.27 Thousand USD | 10.43% |
| 2017 | 456.66 Thousand USD | 53.78% |
| 2016 | 296.95 Thousand USD | 51.5% |
| 2015 | 196.01 Thousand USD | 553.37% |
| 2014 | 30 Thousand USD | -87.5% |
| 2013 | 240 Thousand USD | 700.0% |
| 2012 | 30 Thousand USD | -99.0% |
| 2011 | 3 Million USD | 29900.0% |
| 2010 | 10 Thousand USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 6800.00 USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 926.66 Thousand USD | 4.35% |
| 2024 Q2 | 961.5 Thousand USD | 3.76% |
| 2023 FY | 888.06 Thousand USD | -17.59% |
| 2023 Q4 | 888.06 Thousand USD | -0.14% |
| 2023 Q1 | 1.21 Million USD | 12.64% |
| 2023 Q2 | 894.37 Thousand USD | -26.32% |
| 2023 Q3 | 889.27 Thousand USD | -0.57% |
| 2022 Q2 | 1.1 Million USD | -1.55% |
| 2022 Q3 | 1.09 Million USD | -0.93% |
| 2022 Q4 | 1.07 Million USD | -1.37% |
| 2022 Q1 | 1.12 Million USD | 2.0% |
| 2022 FY | 1.07 Million USD | -1.87% |
| 2021 Q3 | 1.12 Million USD | 6.74% |
| 2021 FY | 1.09 Million USD | 5.55% |
| 2021 Q2 | 1.05 Million USD | -4.71% |
| 2021 Q4 | 1.09 Million USD | -2.45% |
| 2021 Q1 | 1.1 Million USD | 6.39% |
| 2020 Q3 | 1.03 Million USD | -1.35% |
| 2020 Q4 | 1.04 Million USD | 0.6% |
| 2020 Q1 | 1.08 Million USD | 10.31% |
| 2020 FY | 1.04 Million USD | 5.99% |
| 2020 Q2 | 1.04 Million USD | -3.18% |
| 2019 Q1 | 552.96 Thousand USD | 9.66% |
| 2019 Q4 | 981.62 Thousand USD | 84.81% |
| 2019 Q2 | 561.27 Thousand USD | 1.5% |
| 2019 Q3 | 531.13 Thousand USD | -5.37% |
| 2019 FY | 981.62 Thousand USD | 94.66% |
| 2018 Q2 | 482.31 Thousand USD | 2.76% |
| 2018 Q3 | 492.62 Thousand USD | 2.14% |
| 2018 Q4 | 504.27 Thousand USD | 2.36% |
| 2018 FY | 504.27 Thousand USD | 10.43% |
| 2018 Q1 | 469.37 Thousand USD | 2.79% |
| 2017 Q3 | 424.15 Thousand USD | 3.75% |
| 2017 Q4 | 456.66 Thousand USD | 7.66% |
| 2017 FY | 456.66 Thousand USD | 53.78% |
| 2017 Q2 | 408.84 Thousand USD | 35.38% |
| 2017 Q1 | 302 Thousand USD | 1.7% |
| 2016 Q4 | 296.95 Thousand USD | 49.47% |
| 2016 Q3 | 198.66 Thousand USD | 0.85% |
| 2016 Q1 | 200 Thousand USD | 0.0% |
| 2016 FY | 296.95 Thousand USD | 51.5% |
| 2016 Q2 | 196.99 Thousand USD | -1.5% |
| 2015 FY | 196.01 Thousand USD | 553.37% |
| 2015 Q4 | 200 Thousand USD | 566.67% |
| 2015 Q3 | 30 Thousand USD | 0.0% |
| 2015 Q2 | 30 Thousand USD | 0.0% |
| 2015 Q1 | 30 Thousand USD | 0.0% |
| 2014 Q2 | 230 Thousand USD | 0.0% |
| 2014 Q1 | 230 Thousand USD | -4.17% |
| 2014 FY | 30 Thousand USD | -87.5% |
| 2014 Q4 | 30 Thousand USD | 9515.38% |
| 2014 Q3 | 312.00 USD | -99.86% |
| 2013 Q2 | 230 Thousand USD | 187.5% |
| 2013 Q4 | 240 Thousand USD | -4.0% |
| 2013 Q1 | 80 Thousand USD | 166.67% |
| 2013 FY | 240 Thousand USD | 700.0% |
| 2013 Q3 | 250 Thousand USD | 8.7% |
| 2012 Q1 | 3 Million USD | 0.0% |
| 2012 Q3 | 110 Thousand USD | -96.54% |
| 2012 Q4 | 30 Thousand USD | -72.73% |
| 2012 FY | 30 Thousand USD | -99.0% |
| 2012 Q2 | 3.18 Million USD | 6.0% |
| 2011 Q2 | 3.09 Million USD | 5050.0% |
| 2011 FY | 3 Million USD | 29900.0% |
| 2011 Q4 | 3 Million USD | -2.28% |
| 2011 Q1 | 60 Thousand USD | 500.0% |
| 2011 Q3 | 3.07 Million USD | -0.65% |
| 2010 Q3 | 20 Thousand USD | 0.0% |
| 2010 Q4 | 10 Thousand USD | -50.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | 10 Thousand USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q3 | 10 Thousand USD | 47.06% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q2 | 6800.00 USD | 0.0% |
| 2009 Q1 | 6800.00 USD | 0.0% |
| 2009 FY | - USD | -100.0% |
| 2008 Q4 | 6800.00 USD | 2166.67% |
| 2008 FY | 6800.00 USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | 300.00 USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 97.845% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 78.455% |
| SQZ Biotechnologies Company | 27.47 Million USD | 96.767% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 97.952% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 97.017% |
| Mesoblast Limited | 118.7 Million USD | 99.252% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 6.349% |
| Genus plc | 233.1 Million USD | 99.619% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 69.695% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 33.903% |
| Marizyme, Inc. | 18.71 Million USD | 95.255% |
| ContraFect Corporation | 2.88 Million USD | 69.175% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -18.409% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -555.461% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 38.598% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 61.819% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 84.305% |
| MultiCell Technologies, Inc. | 202.58 USD | -438276.938% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 98.455% |
| EV Biologics, Inc. | 1.49 Million USD | 40.588% |
| Q BioMed Inc. | 4.1 Million USD | 78.393% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 97.317% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -40.945% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 27.703% |
| Biomind Labs Inc. | 735.54 Thousand USD | -20.736% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.482% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 93.167% |
| Skye Bioscience, Inc. | 4.61 Million USD | 80.758% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -527.527% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 84.874% |
| IMV Inc. | 28.88 Million USD | 96.925% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -3352.949% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 60.677% |
| GB Sciences, Inc. | 1.75 Million USD | 49.522% |
| Alpha Cognition Inc. | 1.22 Million USD | 27.23% |
| HST Global, Inc. | 98.31 Thousand USD | -803.248% |
| CSL Limited | 12.18 Billion USD | 99.993% |
| Halberd Corporation | 150 Thousand USD | -492.043% |
| Enzolytics Inc. | 996.33 Thousand USD | 10.867% |
| Resverlogix Corp. | 6.49 Million USD | 86.319% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -85.982% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -247.454% |
| argenx SE | 20 Million USD | 95.56% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 98.051% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 67.214% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -8585.222% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.787% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -342.669% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 62.962% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -287.309% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 98.687% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 70.654% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -146.883% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 95.631% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -497.403% |
| BioStem Technologies, Inc. | 4.71 Million USD | 81.151% |
| ONE Bio Corp. | 19.71 Million USD | 95.495% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -254.967% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -257.054% |
| Agentix Corp. | 50 Thousand USD | -1676.128% |
| LadRx Corporation | 33.6 Thousand USD | -2542.576% |
| Cell Source, Inc. | 9.25 Million USD | 90.404% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -17.437% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -17.437% |
| NovAccess Global Inc. | 2.19 Million USD | 59.631% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 87.444% |
| Itoco Inc. | 228.37 Thousand USD | -288.859% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -320.933% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 82.178% |
| Kadimastem Ltd | 891.22 Thousand USD | 0.355% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -120.994% |
| CytoDyn Inc. | 30.07 Million USD | 97.047% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -83.377% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -152.401% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 88.644% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -624.95% |
| Rebus Holdings, Inc. | 310 Thousand USD | -186.472% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 81.246% |
| International Stem Cell Corporation | 4.17 Million USD | 78.744% |
| Bioxytran, Inc. | 1.92 Million USD | 53.867% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1322.883% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 59.28% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 89.321% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 89.656% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 42.907% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -231.367% |
| Neutra Corp. | 54.15 Thousand USD | -1539.826% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 51.472% |
| PureTech Health plc | 25.51 Million USD | 96.519% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 27.459% |
| IXICO plc | 472.02 Thousand USD | -88.14% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 94.271% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.574% |
| CSL Limited | 12.18 Billion USD | 99.993% |
| Cellectis S.A. | 92.77 Million USD | 99.043% |